journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thoracic Oncology

journal
https://www.readbyqxmd.com/read/28911956/alk-and-ros1-double-rearranged-lung-squamous-cell-carcinoma-responding-to-crizotinib-treatment-a-case-report
#1
Qiong Li, Jian Wu, Li-Xu Yan, Jun-Wei Huang, Zhou Zhang, Jin-E Zhang, Xing-Lin Gao, Ze-Ru Luo, Jing Liu, Shi-Fang Yang, Yan-Hui Liu
No abstract text is available yet for this article.
September 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28911955/brief-report-somatic-mutations-and-ancestry-markers-in-hispanic-lung-cancer-patients
#2
Nicholas T Gimbrone, Bhaswati Sarcar, Edna R Gordian, Jason I Rivera, Christian Lopez, Sean J Yoder, Jamie K Teer, Eric A Welsh, Alberto A Chiaporri, Matthew B Schabath, Gary W Reuther, Julie Dutil, Miosotis Garcia, Ronald Ventosilla-Villanueva, Luis Vera-Valdivia, Alejandro Yabar-Berrocal, Rodrigo Motta-Guerrero, Pedro G Santiago-Cardona, Teresita Muñoz-Antonia, W Douglas Cress
INTRODUCTION: To address the lack of genomic data from Hispanic/Latino (H/L) patients with lung cancer, the Latino Lung Cancer Registry was established to collect patient data and biospecimens from these patients. METHODS: This retrospective observational study examined lung cancer tumor samples from 163 H/L patients, and tumor-derived DNA was subjected to targeted-exome sequencing (>1000 genes, including EGFR, KRAS, STK11, and TP53) and ancestry analysis. Mutation frequencies in this H/L cohort were compared with those in a similar cohort of non-Hispanic white (NHW) patients and were correlated with ancestry, sex, smoking status, and tumor histology...
September 11, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28882585/prognostic-impact-of-margin-distance-and-tumor-spread-through-air-spaces-in-limited-resection-for-primary-lung-cancer
#3
Kyohei Masai, Hiroyuki Sakurai, Aoi Sukeda, Shigeki Suzuki, Keisuke Asakura, Kazuo Nakagawa, Hisao Asamura, Shun-Ichi Watanabe, Noriko Motoi, Nobuyoshi Hiraoka
OBJECTIVES: To investigate the relationships between clinicopathological prognostic factors, including, surgical margin distance and tumor spread through air spaces (STAS), and recurrence after limited resection for primary lung cancer. METHODS: We identified 508 limited resection cases (12.8%) and examined their clinicopathological features. Using Cox regression analysis, we examined the significant prognostic factors for recurrence of limited resection. Finally, we conducted a histopathological evaluation of tumor STAS...
September 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28882584/prophylactic-cranial-irradiation-pci-vs-active-mri-surveillance-for-small-cell-lung-cancer-the-case-for-equipoise
#4
REVIEW
Chad G Rusthoven, Brian D Kavanagh
Prophylactic cranial irradiation (PCI) for small-cell lung cancer (SCLC) offers a consistent reduction in the incidence of brain metastases (BM), at the cost of measurable toxicity to neurocognitive function and quality of life in the setting of characteristic pathologic changes to the brain. The sequelae of PCI have historically been justified by the perception of an overall survival (OS) advantage specific to SCLC. This rationale has now been challenged by a randomized trial in extensive-stage SCLC demonstrating equivalent progression-free survival and a trend toward improved OS with PCI omission in the context of modern MRI staging, surveillance, and salvage therapy...
September 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843363/pembrolizumab-induced-encephalopathy-a-review-of-neurological-toxicities-with-immune-checkpoint-inhibitors
#5
Sophie Feng, Jermaine Coward, Elizabeth McCaffrey, John Coucher, Paul Kalokerinos, Kenneth O'Byrne
The use of immune checkpoint inhibitor (ICI) therapy in the treatment of solid organ malignancies is becoming increasingly common. This has prompted the recognition of a new class of immune related adverse effects (irAEs) which stem from the upregulation of T cell activity causing autoimmunity. Neurological irAEs are a rare complication of ICIs that can lead to long term morbidity. We report a rare case of encephalopathy following treatment with pembrolizumab, where the patient achieved durable disease response despite discontinuation of therapy...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843362/national-cancer-data-base-report-on-pneumonectomy-versus-lung-sparing-surgery-for-malignant-pleural-mesothelioma
#6
Vivek Verma, Christopher A Ahern, Christopher G Berlind, William D Lindsay, Sonam Sharma, Jacob Shabason, Melissa J Culligan, Surbhi Grover, Joseph S Friedberg, Charles B Simone
INTRODUCTION: Controversy exists regarding the optimal surgical technique for malignant pleural mesothelioma (MPM). We evaluated national practice patterns and outcomes of MPM treated with extrapleural pneumonectomy (EPP) versus lung-sparing extended pleurectomy/decortication (P/D). METHODS: The National Cancer Data Base was queried for newly-diagnosed MPM patients undergoing EPP or P/D. Multivariable logistic regression ascertained clinical factors independently associated with P/D receipt...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843361/germline-mutations-in-dna-repair-genes-in-lung-adenocarcinoma
#7
Erin M Parry, Dustin L Gable, Susan E Stanley, Sara E Khalil, Valentin Antonescu, Liliana Florea, Mary Armanios
INTRODUCTION: While lung cancer is generally thought to be environmentally provoked, anecdotal familial clustering has been reported suggesting there may be genetic susceptibility factors. We systematically tested whether germline mutations in eight candidate genes may be risk factors for lung adenocarcinoma. METHODS: We studied lung adenocarcinoma cases for whom germline sequence data had been generated as part of The Cancer Genome Atlas (TCGA) project, but that had not been previously analyzed...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843360/prognostic-value-of-primary-tumor-volume-changes-on-kv-cbct-during-definitive-chemoradiotherapy-for-stage-iii-non-small-cell-lung-cancer
#8
P Wald, X Mo, C Barney, D Gunderson, A K Haglund, J Bazan, J Grecula, A Chakravarti, T Williams, D P Carbone, M Xu-Welliver
INTRODUCTION: Kilo-voltage cone beam computed tomography (kV-CBCT) allows for tumor localization and response assessment during definitive chemoradiotherapy for locally advanced non-small cell lung cancer (LA-NSCLC). We hypothesize that significant tumor volume loss occurs early during radiotherapy, and that the extent of volume loss correlates with clinical outcomes. METHODS: 52 patients with LA-NSCLC treated with definitive chemoradiotherapy were reviewed. kV-CBCT images were used to contour primary gross tumor volumes (GTV) at four time points during treatment...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843359/combination-osimertinib-and-gefitinib-in-c797s-and-t790m-egfr-mutated-non-small-cell-lung-cancer
#9
Surein Arulananda, Hongdo Do, Ashan Musafer, Paul Mitchell, Alexander Dobrovic, Thomas John
INTRODUCTION: Osimertinib, a third generation Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) has demonstrated efficacy in tumours harbouring the EGFR T790M resistance mutation. Inevitably, resistance to 3(rd) generation inhibitors result in disease progression, with the EGFR C797S mutation being one of several resistance pathways identified to date. Based on preclinical data, we report the first known case of a patient harbouring the T790M and C797S mutations in trans treated with combination gefitinib and osimertinib...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843358/brief-report-baseline-and-on-treatment-characteristics-of-serum-tumor-markers-in-stage-iv-oncogene-addicted-adenocarcinoma-of-the-lung
#10
Sinead A Noonan, Tejas Patil, Dexiang Gao, Gentry G King, Jessica R Thibault, Xian Lu, Paul A Bunn, Robert C Doebele, W Thomas Purcell, Anna E Barón, D Ross Camidge
INTRODUCTION: The role of serum tumor markers in the modern management of advanced non-small cell lung cancer remains poorly described. METHODS: A single center retrospective analysis of available CEA, CA125, CA19.9 and CA27.29 levels at baseline and on treatment in stage IV lung adenocarcinoma by oncogenic driver was conducted. RESULTS: 142 patients were analyzed (ALK=60, EGFR=50, ROS1=4 and KRAS=28). 82% of patients had at least one marker; 95% if all four markers measured (CA27...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28843357/the-role-of-thoracic-surgery-in-the-therapeutic-management-of-metastatic-non-small-cell-lung-cancer
#11
REVIEW
Elizabeth A David, James M Clark, David T Cooke, Joy Melnikow, Karen Kelly, Robert J Canter
INTRODUCTION: The majority of non-small cell lung cancer (NSCLC) patients are diagnosed with advanced stage disease for whom the prognosis is poor and survival is typically measured in months. Standard therapeutic treatment regimens for patients with stage IV NSCLC typically include chemotherapy and palliative radiation. Despite newer regimens that may include molecularly targeted therapy and immunotherapy, the overall 5-year survival for stage IV disease remains low at 4-6%. Although therapeutic surgery is performed in a minority of cases, accumulating data suggest that thoracic surgery may play several beneficial roles for these patients...
August 23, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28818609/multicenter-comparison-of-22c3-pharmdx-agilent-and-sp263-ventana-assays-to-test-pd-l1-expression-for-nsclc-patients-to-be-treated-with-immune-checkpoint-inhibitors
#12
Antonio Marchetti, Massimo Barberis, Renato Franco, Graziano De Luca, Maria Vittoria Pace, Stefania Staibano, Marco Volante, Fiamma Buttitta, Elena Guerini-Rocco, Luisella Righi, Tommaso D'antuono, Giorgio V Scagliotti, Carmine Pinto, Gaetano De Rosa, Mauro Papotti
INTRODUCTION: Among the several agents targeting the programmed cell death 1 (PD-1) pathway, pembrolizumab is currently the only one approved for the treatment of non-small cell lung cancer patients in association with a companion diagnostic assay, the anti-programmed cell death ligand 1 (PD-L1) immunohistochemical (IHC) 22C3 PharmDx (Agilent) using the Dako Autostainer. However, the Dako platform is not present in each pathology department and this technical limitation is a major problem for the diffusion of the PD-L1 IHC predictive test for pembrolizumab...
August 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28818608/potential-resistance-mechanisms-revealed-by-targeted-sequencing-from-lung-adenocarcinoma-patients-with-primary-resistance-to-epidermal-growth-factor-receptor-egfr-tyrosine-kinase-inhibitors-tkis
#13
Jia Zhong, Lei Li, Zhijie Wang, Hua Bai, Gai Fei, Jian Chunduan, Jun Zhao, Minglei Zhuo, Yuyang Wang, Shuhang Wang, Wanchun Zang, Meina Wu, Tongtong An, Guanhua Rao, Jie Wang
BACKGROUND: EGFR-TKIs have greatly improved the prognosis of lung adenocarcinoma. However, approximately 5%-10% lung adenocarcinoma patients with EGFR sensitive mutations have primary resistance to EGFR-TKIs treatment. The underlying mechanism is unknown. METHODS: This study used next-generation sequencing (NGS) to explore the mechanisms of primary resistance by analyzing 11 patients with primary resistance and 11 patients sensitive to EGFR-TKIs. NGS targeted sequencing was performed on the Illumina X platform for 483 cancer-related genes...
August 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28818607/potential-impact-of-including-time-to-first-cigarette-into-risk-models-for-selecting-ever-smokers-for-lung-cancer-screening
#14
Fangyi Gu, Li C Cheung, Neal D Freedman, Hormuzd A Katki, Neil E Caporaso
BACKGROUND: Selecting individuals based on model-predicted risks has been reported to improve lung cancer screening efficiency. Time-to-first-cigarette (TTFC), a nicotine dependency measurement, has been a strong independent lung-cancer risk predictor, based on case-control studies. AIMS: To verify the TTFC-lung cancer association in the prospective National Lung Screening Trial (NLST), and evaluate whether adding TTFC can improve lung-cancer risk-prediction models...
August 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28818606/recent-advances-in-targeting-ros1-in-lung-cancer
#15
REVIEW
Jessica J Lin, Alice T Shaw
ROS1 is a validated therapeutic target in non-small cell lung cancer (NSCLC). In a phase I study, the multi-targeted MET/ALK/ROS1 inhibitor crizotinib demonstrated remarkable efficacy in ROS1-rearranged NSCLCs, and consequently gained approval by the United States Food and Drug Administration as well as the European Medicines Agency in 2016. However, similar to other oncogene-driven lung cancers, ROS1-rearranged lung cancers treated with crizotinib eventually acquire resistance, leading to disease relapse. Novel ROS1 inhibitors and therapeutic strategies are therefore needed...
August 14, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28804012/incidence-of-second-malignancy-after-successful-treatment-of-limited-stage-small-cell-lung-cancer-and-its-effects-on-survival
#16
Miho Kono, Pamela K Allen, Steven H Lin, Xiong Wei, Melenda Jeter, James W Welsh, James D Cox, Ritsuko Komaki
INTRODUCTION: Extended survival outcomes from improved treatments for patients with cancer come with an increased risk of developing a metachronous second malignancy (MSM). We evaluated the incidence of MSM after successful treatment of SCLC and compared survival between SCLC patients who developed MSM and those who did not. METHODS: Selection criteria were a diagnosis of limited-stage SCLC and receipt of ≥45 Gy radiotherapy and chemotherapy at a single institution in 1985-2012...
August 10, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28782726/validation-of-the-stage-groupings-in-the-eighth-edition-of-the-tnm-classification-for-lung-cancer
#17
Xizhao Sui, Wei Jiang, Haiqing Chen, Fan Yang, Jun Wang, Qun Wang
INTRODUCTION: The aim of this study was to validate stage groupings in the eighth edition of the TNM classification in an independent Chinese cohort. METHODS: We retrospectively analyzed a total of 3599 patients with pathological stage IA to IIIA (seventh edition of the TNM) NSCLC who underwent surgical treatment in two surgical centers in the People's Republic of China between 2005 and 2012. All patients were reclassified according to the eighth edition of the TNM classification...
August 4, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28782727/adequacy-of-intra-operative-nodal-staging-during-surgical-resection-of-nsclc-influencing-factors-and-its-relationship-to-survival
#18
Tim Edwards, Haval Balata, Mohamed Elshafi, Philip Foden, Paul Bishop, Eustace Fontaine, Mark Jones, Piotr Krysiak, Kandadai Rammohan, Rajesh Shah, Philip Crosbie, Richard Booton, Matthew Evison
INTRODUCTION: Adequate intra-operative lymph node sampling is a fundamental part of lung cancer surgery but adherence to standards is not well known. This study sought to measure the adequacy of intra-operative lymph node sampling at a regional Thoracic Surgery Centre and a tertiary lung cancer centre in the United Kingdom. METHODS: This retrospective study analysed the pathological reports from NSCLC resections over a four year period 2011-2014. Adequacy of sampling was assessed against IASLC recommendations of at least three mediastinal lymph node stations, station 7 in all patients, stations 5/6 in left upper lobe tumours and station 9 in lower lobe tumours...
August 3, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28779874/brief-report-met-exon-14-alterations-and-new-resistance-mutations-to-tyrosine-kinase-inhibitors-risk-of-inadequate-detection-with-current-amplicon-based-ngs-panels
#19
Brigitte Poirot, Ludovic Doucet, Shirine Benhenda, Jérôme Champ, Véronique Meignin, Jacqueline Lehmann-Che
INTRODUCTION: Targeted therapies, as tyrosine kinase inhibitors (TKI), have dramatically improved the treatment of lung adenocarcinoma and detection of activating mutations of genes like EGFR or ALK is now mandatory in clinical setting. However, additional targetable alterations are continuously described and force us to adapt our detection methods. We evaluate here the ability of 8 amplicon-based next generation sequencing (NGS) panels to detect the recently described MET exon 14 alterations or new resistance-mutations to TKI...
August 2, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/28774862/nivolumab-enhances-the-inflammation-of-the-irradiation-field-in-advanced-non-small-cell-lung-cancer
#20
Hiromi Furuta, Tatsuya Yoshida, Junichi Shimizu, Natsuo Tomita, Yasushi Yatabe, Toyoaki Hida
No abstract text is available yet for this article.
July 31, 2017: Journal of Thoracic Oncology
journal
journal
41363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"